All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 6, 2022

Disease categories and therapies

  • Disease categories and therapies
    • Aesthetics
    • Anesthesiology
    • Cancer
    • Cardiovascular
    • Dental
    • Dermatologic
    • Diabetes
    • Diversified
    • Ear, Nose and Throat
    • Endocrine/Metabolic
    • Gastrointestinal
    • Genitourinary/Sexual Function
    • Hematologic
    • Immune
    • Infection
    • Inflammatory
    • Musculoskeletal
    • Neonatal/Pediatrics
    • Nephrology
    • Neurology/Psychiatric
    • Obesity
    • Obstetrics
    • Ocular
    • Oncology
    • Ophthalmic
    • Orthopedics
    • Respiratory
    • Toxicity/Intoxication
    • Urology
Home » Topics » Disease categories and therapies
  • Liver and dna
    Oct. 19, 2021
    By Gina Lee

    Hansoh and Olix ink $450M+ liver-focused siRNA therapeutics deal for greater China

    In a deal that could be worth more than $450 million, Olix Pharmaceuticals Inc. and Hansoh Pharmaceutical Group Co. Ltd. have agreed to discover, develop, and commercialize siRNA therapeutics for various liver-based targets implicated in cardiovascular, metabolic, and other indications.
  • Liver and dna
    Oct. 13, 2021
    By Gina Lee

    Hansoh and Olix ink $450M+ liver-focused siRNA therapeutics deal for greater China

    In a deal that could be worth more than $450 million, Olix Pharmaceuticals Inc. and Hansoh Pharmaceutical Group Co. Ltd. have agreed to discover, develop, and commercialize siRNA therapeutics for various liver-based targets implicated in cardiovascular, metabolic, and other indications.
  • Baby infant
    Feb. 8, 2021
    By Nuala Moran

    Single-cell resolution reveals cell type, targets for neuroblastoma

    The largest single cell transcriptomics study of neuroblastoma to date has discovered that this childhood cancer arises from a single type of embryonic cell, the sympathoblast. 

Read More

Authors

  • Randy Osborne
  • Peter Winter
  • Brian Orelli
  • Nuala Moran
  • Gina Lee
  • Doris Yu
More Authors
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing